Featured Research

from universities, journals, and other organizations

Calcium And Vitamin D Most Effective For Treatment Of Crohn's-related Bone Loss

Date:
February 2, 2005
Source:
American Gastroenterological Association
Summary:
According to a study published today in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, the addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.

Bethesda, Maryland (Feb. 1, 2005) – According to a study published today in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, the addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial. Moreover, the study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year.

"Patients with Crohn's often suffer loss of bone mass and an increased number of bone fractures due to treatment with corticosteroids, poor nutrition, active inflammation and calcium and vitamin D deficiencies," said Charles Bernstein, MD, author of an editorial appearing in this month's journal. "Calcium and vitamin D have long been used to enhance bone mass in people with Crohn's, and findings of these studies show it to be sufficient in maintaining BMD in these patients."

Crohn's disease is an inflammatory bowel disease that causes chronic inflammation of the intestinal wall. While the cause of Crohn's is relatively unknown, it usually starts during the teenage years or early adulthood and is characterized by pain in the abdomen, diarrhea and weight loss. According to the most recent data from the National Health Interview Survey, there are more than two million prevalent cases of Crohn's disease in the United States.

According to results of the study from researchers at the University of Alberta, adding the bone-building drug etidronate (Ditronel) to calcium and vitamin D therapy to treat bone loss in people with Crohn's disease adds no additional benefit. This study aimed to assess the efficacy of etidronate on bone loss in patients with Crohn's disease, an effect that has never before been studied in patients who were not menopausal or on corticosteroid therapy.

"Calcium and vitamin D therapy alone provide benefit to Crohn's patients who suffer from osteoporosis and osteopenia," said Richard Fedorak, MD, study author. "We encourage physicians to look for loss of bone density in high risk patients with Crohn's disease and to start calcium and vitamin D therapy immediately if there is either osteoporosis or osteopenia."

Prevention and treatment of low BMD associated with Crohn's disease includes vitamin D and calcium supplementation, education and lifestyle changes such as regular exercise and smoking cessation. Further randomized clinical trials are underway to determine if newer bone-building drugs will have additional beneficial effects on building bone mass in Crohn's patients. The results of those studies will not be available until next year. Until then, researchers suggest vitamin D and calcium supplementation as the primary treatment for bone loss in these patients.

"These results imply that physicians should only consider BMD testing and drug therapy for patients who are at higher risk for osteoporosis and fractures, not those who merely have Crohn's disease as a diagnosis," said Bernstein.

###

About the StudyResearchers from the University of Alberta in Canada conducted a randomized clinical trial of 150 patients who had Crohn's disease and who attended either the Inflammatory Bowel Disease Referral Clinic (Alberta) or Mt. Sinai Hospital (Toronto). Study participants were classified into three groups following initial measure of BMD: normal bone density, osteopenia and osteoporosis. Patients with osteopenia and osteoporosis were then randomized to calcium and vitamin D supplementation or to etidronate plus calcium and vitamin D supplementation groups.

###

About the AGA

The American Gastroenterological Association (AGA) is dedicated to the mission of advancing the science and practice of gastroenterology. Founded in 1897, the AGA is the oldest medical-specialty society in the United States. The AGA's 14,000 members include physicians and scientists who research, diagnose and treat disorders of the gastrointestinal tract and liver. On a monthly basis, the AGA publishes two highly respected journals, Gastroenterology and Clinical Gastroenterology and Hepatology. The AGA's annual meeting is Digestive Disease Week, which is held each May and is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

About Clinical Gastroenterology and Hepatology

The mission of Clinical Gastroenterology and Hepatology is to provide readers with a broad spectrum of themes in clinical gastroenterology and hepatology. This monthly peer-reviewed journal includes original articles as well as scholarly reviews, with the goal that all articles published will be immediately relevant to the practice of gastroenterology and hepatology. For more information, visit http://www.cghjournal.org.


Story Source:

The above story is based on materials provided by American Gastroenterological Association. Note: Materials may be edited for content and length.


Cite This Page:

American Gastroenterological Association. "Calcium And Vitamin D Most Effective For Treatment Of Crohn's-related Bone Loss." ScienceDaily. ScienceDaily, 2 February 2005. <www.sciencedaily.com/releases/2005/02/050201100614.htm>.
American Gastroenterological Association. (2005, February 2). Calcium And Vitamin D Most Effective For Treatment Of Crohn's-related Bone Loss. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2005/02/050201100614.htm
American Gastroenterological Association. "Calcium And Vitamin D Most Effective For Treatment Of Crohn's-related Bone Loss." ScienceDaily. www.sciencedaily.com/releases/2005/02/050201100614.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins